전체 프로그램 | 바이오모아

CGTBiologicstaleXiangyang No.1 People's HospitalPhase 2

autologous NK cell (autologous NK cell)

NK Cell; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 0.667%임상시험 1상태 RECRUITING

CGTBiologicstaleYuLiPhase 2

dual target CAR-T cell therapy (dual target CAR-T cell therapy)

Lymphoma, B-Cell; Relapse/Recurrence · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 ACTIVE

CGTBiologicstaleUniversity of PennsylvaniaPhase 1

huCART19 Cells (huCART19 Cells)

Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleUniversity of PennsylvaniaPhase 1

huCART19-IL18-eDHFR cells (huCART19-IL18-eDHFR cells)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleBaylor College of MedicinePhase 1

i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells (i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells)

Relapsed Neuroblastoma; Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleShahid Beheshti University of M…Phase 3

injection of bevacizumab (injection of bevacizumab)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleShahid Beheshti University of M…Phase 3

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 ACTIVE

CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

pCAR-19B cells (pCAR-19B cells)

Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 1상태 ACTIVE

CGTBiologicstaleBeijing GoBroad HospitalPhase 1

prior-HSCT donor-derived FL-33 CAR T therapy (prior-HSCT donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

13 / 13 페이지

← 이전다음 →